GLP-1 Agonists Explained: Semaglutide, Tirzepatide & More
GLP-1 agonists have become some of the most talked-about medications in weight management. Names like semaglutide, Ozempic, Wegovy, tirzepatide, Mounjaro, and Zepbound are everywhere—but understanding how they relate to one another isn't always easy.
Is semaglutide a GLP-1 agonist? Is tirzepatide one too? Are Ozempic and Wegovy the same thing? And what exactly are these medications doing in the body?
The simplest place to start is this:
GLP-1 receptor agonists are medications that mimic some of the effects of a hormone your body naturally produces called glucagon-like peptide-1, or GLP-1.
They can affect blood sugar, digestion, appetite, and feelings of fullness. Some GLP-1 medications are approved to treat type 2 diabetes, some are approved for chronic weight management, and certain active ingredients are sold under different brand names for different indications.
Here's how it all fits together.
What Is a GLP-1 Agonist?
GLP-1 stands for glucagon-like peptide-1.
It's a naturally occurring hormone involved in the body's response to food. Among other things, GLP-1 helps stimulate insulin secretion when glucose levels are elevated, slows movement of food through the digestive tract, and is involved in the regulation of appetite and food intake.
A GLP-1 receptor agonist, often shortened to GLP-1 agonist or GLP-1 RA, is a medication that activates GLP-1 receptors.
In plain English, these medications are designed to produce some of the same effects as your body's natural GLP-1—but with effects that can last much longer.
That can influence both blood glucose management and appetite, which helps explain why this class of medications has become important in the treatment of type 2 diabetes and obesity.
How Do GLP-1 Agonists Work?
You don't need to understand every biochemical detail to understand the basic idea.
GLP-1 receptor agonists affect several processes at once.
They influence insulin and blood sugar
When blood glucose is elevated, GLP-1 receptor activation can increase glucose-dependent insulin secretion.
This is one of the reasons GLP-1 agonist drugs have been widely used in the treatment of type 2 diabetes.
They can slow digestion
GLP-1 medications can slow gastric emptying, meaning food moves through the stomach more slowly.
That effect can contribute to feeling full for longer, although the way an individual experiences the medication can vary.
They affect appetite
GLP-1 receptors are found in areas of the brain involved in appetite regulation. By acting on these pathways, GLP-1 medications can reduce appetite and food intake.
For someone using one of these medications for weight management, that can mean eating feels different than it did before treatment.
You may become satisfied with less food. Hunger may feel different. Some people also describe changes in the frequency or intensity of thoughts and urges surrounding food—sometimes referred to informally as "food noise."
Those experiences are part of why tracking more than weight can be useful during a GLP-1 weight loss journey.
Is Semaglutide a GLP-1 Agonist?
Yes.
Semaglutide is a GLP-1 receptor agonist.
You may recognize it better by some of its brand names.
Ozempic contains semaglutide and is FDA-approved for specific uses in people with type 2 diabetes.
Wegovy also contains semaglutide and is FDA-approved for chronic weight management in eligible patients, among other approved indications.
Semaglutide is also available in an oral formulation.
This highlights an important point: the active ingredient and brand name aren't necessarily interchangeable.
Two medications can contain the same active ingredient while having different FDA-approved indications, formulations, doses, or instructions.
So although people sometimes casually use "Ozempic" and "semaglutide" as though they mean exactly the same thing, that's not technically accurate.
What About Tirzepatide?
Tirzepatide belongs in this conversation, but there's an important distinction.
Tirzepatide activates both GLP-1 and GIP receptors.
GIP stands for glucose-dependent insulinotropic polypeptide. Because tirzepatide acts on both GIP and GLP-1 receptors, it's generally described as a dual GIP/GLP-1 receptor agonist.
That's different from semaglutide, which acts on the GLP-1 receptor.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. These brand-name medications have different FDA-approved uses.
So when you hear semaglutide and tirzepatide discussed together, remember:
Semaglutide → GLP-1 receptor agonist
Tirzepatide → dual GIP/GLP-1 receptor agonist
They have overlapping effects, but they are not the same medication.
We'll explore those differences more closely in our guide to Semaglutide vs. Tirzepatide.
GLP-1 Medications Aren't All the Same
Semaglutide may be receiving enormous attention today, but it isn't the only GLP-1 receptor agonist.
The category includes active ingredients such as:
semaglutide;
liraglutide;
dulaglutide;
exenatide; and
lixisenatide.
And then there's tirzepatide, which acts on both GIP and GLP-1 receptors.
Some of these medications are used primarily for type 2 diabetes, while certain medications have FDA-approved indications for chronic weight management.
For example, FDA-approved medications for chronic weight management include Wegovy (semaglutide) and Zepbound (tirzepatide) for eligible patients.
The fact that medications belong to the same general family—or are frequently discussed together—doesn't mean they are interchangeable.
Different medications can have different indications, dosing schedules, contraindications, warnings, side effects, and instructions.
Your healthcare professional should determine which medication, if any, is appropriate for you.
GLP-1 Agonists and Weight Loss
Why have GLP-1 agonists become so closely associated with weight loss?
One major reason is their effect on appetite and food intake.
For some people, managing weight isn't simply a matter of knowing what they "should" eat. Hunger and appetite are influenced by complex biological signals.
Medications that affect GLP-1 pathways can alter some of those signals.
But medication doesn't make the rest of your experience irrelevant.
In fact, starting a GLP-1 medication can give you an opportunity to pay closer attention to what is changing.
You might notice:
you're satisfied with smaller portions;
your hunger feels different at particular times of day;
thoughts about food become less frequent or intense;
certain foods feel different than they did before;
your energy changes;
you're becoming more consistent with movement;
your body measurements change even during a slow week on the scale; or
certain symptoms seem to follow a pattern.
Those observations can easily disappear into memory unless you record them.
If you're using semaglutide, tirzepatide, or another GLP-1-based medication as part of a weight-management plan, the Semaglutide Weight Loss Tracker gives you one place to document your medication, weight, symptoms, food noise, meals, workouts, measurements, habits, and weekly reflections for 26 weeks. Get your copy and start tracking the patterns behind your progress—not just pounds lost.
Why Tracking Your GLP-1 Journey Matters
When people begin a weight loss medication, it's tempting to ask one question every week:
"How much weight did I lose?"
That's understandable, but it gives you only one data point.
A six-month weight loss journey contains hundreds of other pieces of information.
How did your appetite change?
How consistently were you moving?
Which habits became easier?
Were there weeks when your measurements changed but your weight didn't?
Did you notice changes in food noise?
When did particular symptoms appear?
Which routines helped you feel your best?
Tracking gives you a way to look for patterns instead of relying entirely on memory.
Research into behavioral weight management has repeatedly examined self-monitoring of behaviors such as diet, activity, and body weight. A systematic review found a consistent positive relationship between self-monitoring and weight-loss outcomes, while also noting limitations in the strength of the available evidence.
That doesn't mean keeping a journal guarantees weight loss.
It means paying attention to your behaviors and progress can be a useful part of a broader weight-management strategy.
What Can You Track While Taking a GLP-1 Medication?
Tracking doesn't need to become a full-time job.
A useful system should make it easier to understand your experience—not make you feel as though you're constantly being graded.
Here are several areas that can be particularly useful to record.
Medication
Record your medication according to the instructions you've received from your healthcare professional.
Depending on your treatment, your personal log might include the date, prescribed dose, method of administration, and—for injectable medications—the injection site.
A medication log is a record, not a dosing guide. Never use a journal or online article to determine or change your prescribed dose.
Weight
A weekly weight tracker can make it easier to see the trend across several months instead of reacting to every individual fluctuation.
Progress is rarely perfectly linear.
Body measurements
The scale isn't the only way your body can change.
Taking periodic measurements can provide another point of comparison as your journey progresses.
Symptoms
Gastrointestinal symptoms are among the commonly reported side effects of GLP-1-based medications.
Rather than trying to remember several weeks of symptoms at your next appointment, recording what you experienced and when can give you a clearer history to discuss with your healthcare professional.
Tracking symptoms isn't the same as diagnosing or treating them. Contact your healthcare professional about concerning, persistent, or severe symptoms rather than waiting for your next journal entry.
Food noise and hunger
Consider giving your food noise or hunger a simple rating each week.
You aren't trying to create a perfect scientific measurement.
You're creating a consistent point of comparison:
"How does this week feel compared with last week?"
Over several months, that can reveal changes you might otherwise forget.
Food and meals
A food tracker can help you notice patterns without requiring you to label every meal as "good" or "bad."
What did you eat?
What kept you satisfied?
Which routines were easiest to maintain?
What would you like to do differently?
That's information—not judgment.
Exercise and movement
Walking, steps, strength training, workouts, distance, repetitions, or other activities can all be tracked according to the goals you've established with your healthcare team.
Habits
Medication can be one component of a much larger health journey.
Tracking habits gives you something else to work toward even during a week when the scale doesn't move the way you hoped.
What About GLP-1 Side Effects?
Like all medications, GLP-1-based treatments can cause side effects.
Common gastrointestinal side effects associated with this medication category can include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, although the specific risks vary by medication.
There are also potentially serious risks and contraindications associated with these drugs.
That's why a symptom journal should never replace medical care.
Instead, think of tracking as a way of creating a more reliable record for conversations with your healthcare professional.
Rather than saying:
"I felt nauseated a lot last month, but I don't remember when."
you may be able to look at your notes and provide a much clearer account of what you experienced.
We'll explore this subject more thoroughly in Common GLP-1 Side Effects and How People Track Them.
A GLP-1 Medication Is One Part of a Bigger Journey
There's a tendency to talk about GLP-1 agonists as though the medication itself is the weight loss journey.
It isn't.
Your journey also includes the behaviors, routines, discoveries, challenges, and decisions happening alongside it.
A medication might change your appetite.
But you're still learning which meals work for you.
It might make portions feel different.
But you're still developing routines around eating.
Your weight might change.
But you're also discovering what kinds of movement you enjoy, which habits you can sustain, and what helps you feel your best.
Those lessons can matter far beyond a single weigh-in.
Turn your GLP-1 journey into something you can learn from. The Semaglutide Weight Loss Tracker is a guided six-month weight loss journal with dedicated space for weekly medication, symptoms, food noise, weight, food, workouts, habits, body measurements, goals, and reflection. Get your copy and build a record of the progress happening both on and beyond the scale.
The Bottom Line on GLP-1 Agonists
GLP-1 receptor agonists are medications that activate receptors for the naturally occurring hormone GLP-1.
They can influence blood sugar, digestion, appetite, and food intake.
Semaglutide is a GLP-1 receptor agonist and is the active ingredient in medications including Ozempic and Wegovy.
Tirzepatide is different: it activates both GIP and GLP-1 receptors and is the active ingredient in Mounjaro and Zepbound.
Although these medications are frequently grouped together in everyday conversation, they aren't interchangeable—and their approved uses, dosing, risks, and instructions can differ.
If you're prescribed one as part of a weight-management plan, understanding the medication is useful.
Understanding your own experience with it can be useful too.
That's where tracking comes in.
Your medication log tells you what you took.
Your scale tells you what you weigh.
But your journal can help you see the much bigger story: what changed, what worked, what was difficult, and which habits you're building along the way.
Medical disclaimer: This article is intended for general educational and informational purposes only and does not provide medical advice, diagnosis, dosing instructions, or treatment recommendations. GLP-1 and related medications are prescription drugs with potential risks, contraindications, and side effects. Talk with a qualified healthcare professional about whether a medication is appropriate for you and how it should be used.
